中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
17期
76-77,138
,共3页
阿托伐他汀%常见问题%合理用药
阿託伐他汀%常見問題%閤理用藥
아탁벌타정%상견문제%합리용약
Atorvastatin%Common problems%Rational drug use
目的:分析阿托伐他汀临床常见问题,为合理用药提供科学依据。方法通过对我院2008年1月~2012年12月期间出现的29例阿托伐他汀不良反应的患者临床资料进行分析,总结阿托伐他汀临床用药常见问题,并提出合理用药措施。结果60岁以上老年患者出现阿托伐他汀不良反应者较高,所占比例为69.0%;患者不良反应发生时间均为药物服用后30min~3个月之内。联合用药患者中服用2~4种药物的患者有21例,所占比例为72.4%。临床不良反应以骨骼、肌肉损害最为常见,所占比例为48.3%。结论阿托伐他汀临床实际用药过程中应加强对患者血液、皮肤、肝、胆等方面的观察与监测,避免患者出现不良反应问题。
目的:分析阿託伐他汀臨床常見問題,為閤理用藥提供科學依據。方法通過對我院2008年1月~2012年12月期間齣現的29例阿託伐他汀不良反應的患者臨床資料進行分析,總結阿託伐他汀臨床用藥常見問題,併提齣閤理用藥措施。結果60歲以上老年患者齣現阿託伐他汀不良反應者較高,所佔比例為69.0%;患者不良反應髮生時間均為藥物服用後30min~3箇月之內。聯閤用藥患者中服用2~4種藥物的患者有21例,所佔比例為72.4%。臨床不良反應以骨骼、肌肉損害最為常見,所佔比例為48.3%。結論阿託伐他汀臨床實際用藥過程中應加彊對患者血液、皮膚、肝、膽等方麵的觀察與鑑測,避免患者齣現不良反應問題。
목적:분석아탁벌타정림상상견문제,위합리용약제공과학의거。방법통과대아원2008년1월~2012년12월기간출현적29례아탁벌타정불량반응적환자림상자료진행분석,총결아탁벌타정림상용약상견문제,병제출합리용약조시。결과60세이상노년환자출현아탁벌타정불량반응자교고,소점비례위69.0%;환자불량반응발생시간균위약물복용후30min~3개월지내。연합용약환자중복용2~4충약물적환자유21례,소점비례위72.4%。림상불량반응이골격、기육손해최위상견,소점비례위48.3%。결론아탁벌타정림상실제용약과정중응가강대환자혈액、피부、간、담등방면적관찰여감측,피면환자출현불량반응문제。
ObjectiveTo analyze the common clinical problems of atorvastatin in order to provide scientific basis for rational drug use.MethodsClinical data of 29 patients having atorvastatin related adverse reactions in our hospital from January 2008 to December 2012 were analyzed.Common clinical drug use problems of atorvastatin were summarized and rational drug use measures were proposed.Results Elderly patients over the age of 60 years were more likely to have atorvastatin related adverse reactions,accounting for 69.0%; The occurrence time of all adverse reactions was within 30 minutes to 3 months after medication. Of the patients using drug combination, 21 patients took 2 to 4 kinds of drugs,accounting for 72.4%.The commonest clinical adverse reactions were skeleton damage and muscle damage,accounting for 48.3%.Conclusion In the clinical practical drug use process of atrovastatin,observation and monitoring of patients' blood,skin, liver and gallbladder should be enhanced to avoid adverse reactions.